Produktname:6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

IUPAC Name:6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine

CAS:17412-23-6
Molekulare Formel:C8H8ClN3
Reinheit:95%+
Katalognummer:CM330120
Molekulargewicht:181.62

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM330120-50mg in stock ƏƏ
CM330120-100mg in stock Ȁǯƻ
CM330120-250mg in stock ȀňǕ
CM330120-1g in stock Ǖǯș
CM330120-5g in stock ŭșș

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:17412-23-6
Molekulare Formel:C8H8ClN3
Schmelzpunkt:-
SMILES-Code:CC1=CC(Cl)=NN2C1=NC(C)=C2
Dichte:
Katalognummer:CM330120
Molekulargewicht:181.62
Siedepunkt:
Mdl-Nr.:MFCD27946129
Lagerung:

Category Infos

Imidazopyridazines
Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

Column Infos

Risdiplam
As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.